Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3112422 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3112421 | 1.00 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL3123712 | 0.89 | SLC6A4 (0.47) | SLC6A4SLC6A3 | |
| SCHEMBL3123706 | 0.89 | SLC6A4 (0.47) | SLC6A4SLC6A3 | |
| SCHEMBL3123700 | 0.89 | SLC6A4 (0.47) | SLC6A4SLC6A3 | |
| SCHEMBL16365793 | 0.86 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL12151967 | 0.86 | SLC6A4 (0.47) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL15196794 | 0.86 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL22492077 | 0.86 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2 | |
| SCHEMBL22492074 | 0.86 | SLC6A3 (0.53) | SLC6A4SLC6A3SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700778-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. (US) | 2010-04-20 | — | — | US | disclosed |
| EP-1385506-B1 | ACYLATED PIPERIDINE DERIVATES AS MELANOCORTIN-4 RECEPTOR AGONISTS | MERCK & CO INC (US) | 2009-05-06 | — | — | EP | disclosed |
| US-7012084-B2 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK & CO., INC. (US) | 2006-03-14 | — | — | US | disclosed |
| US-20060025442-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2006-02-02 | — | — | US | disclosed |
| US-20040092501-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MERCK SHARP & DOHME CORP. | 2004-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060025442-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | SLC6A4 371/4885SLC6A3 968/4885SLC6A2 1375/4885 |
| US-20040092501-A1 | Acylated piperidine derivatives as melanocortin-4 receptor agonists | MC4R, MC5R, MC3R | SLC6A4 371/4885SLC6A3 968/4885SLC6A2 1375/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.